Publications

509 Publications Available
November 29, 2018
Journal of Molecular Cell Biology

CTD2 researchers at Emory University identify novel role for large tumor suppressor 2, LATS2, as a regulator of the ASK1-mediated stress response pathway which may lead to new strategies to control cellular response to stress in normal cells and diseases.

November 28, 2018
Cell Systems

UCSF scientists developed a bioinformatic approach, MAGNETIC, which integrates multi-omic data from cancer patients with pharmacogenomic data from cell lines into a small set of pathway-enriched gene modules. These modules connect tumor and cell line biomarkers and may inform therapeutic targets.

November 13, 2018
Blood

CTD2 scientists at Oregon Health and Science University performed genetic and small-molecule screens and identified CSF1R as a novel therapeutic target of acute myeloid leukemia.

November 06, 2018
Cancer Research

Study demonstrates that EGFR and EGFRvIII cooperate through KRAS, to upregulate chemokine CCL2 and promote infiltration of macrophages in glioblastoma.

November 02, 2018
Nature Communications

CTD2 scientists studied the functional consequences of missense mutations of cell surface protein kinase receptor, PDGFRA, identified from different tumor types. These studies identified a driver mutation in the extracellular domain of PDFRA that are resistant to PDFR inhibitors.

November 01, 2018
Leukemia

CTD2 scientists at OHSU demonstrated that sequential therapy with PARP and either WEE1 or ATR inhibitors is effective and potentially less toxic in multiple relevant cancer models.

October 30, 2018
Cell Reports

Researchers analyzed The Cancer Genome Atlas multidimensional “omic” data using the stems-biology approaches. This study identified that the Hippo signaling pathway plays a critical role in tumor progression in squamous cell carcinoma and could be a potential therapeutic target.

October 17, 2018
Nature

This manuscript presents the molecular characteristics and drug exposure response for a large number of clinically well annotated adult AML cases. These data will reveal potential novel treatment options that will be tested in clinical trials.

Pages

CSV

.